Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 4th, 2026

LECO_Weekly-Healthcare-News_5-4-2026Download
  1. UCB (ENX:UCB) to acquire clinical-stage biotech Candid Therapeutics for up to $2.2 billion to expand its immunology pipeline with novel T-cell engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics for $2 billion in upfront payments and up to $200 million in potential development milestones. The transaction, which hijacks Candid’s planned reverse merger with Rallybio, brings a pipeline of T-cell engagers (TCEs) led by cizutamig (BCMAxCD3), a Phase 1/2-ready bispecific antibody demonstrating deep B-cell and plasma cell depletion with manageable safety in autoimmune patients. This deal positions UCB to compete directly in the emerging TCE autoimmune field alongside Gilead, accelerating its strategy in high-unmet-need immune-mediated diseases through off-the-shelf, outpatient-compatible therapies. Candid’s additional assets, including a CD20xCD3 bispecific and preclinical trispecific TCEs, further strengthen UCB’s next-generation immunology platform. (Link)
  2. Chiesi Group to acquire KalVista Pharmaceuticals (NASD:KALV) for approximately $1.9 billion to strengthen its global rare disease portfolio Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) for $27.00 per share in cash, representing an equity value of approximately $1.9 billion. The transaction, Chiesi’s largest acquisition to date, adds EKTERLY® (sebetralstat), the first oral, on-demand plasma kallikrein inhibitor for hereditary angioedema (HAE) attacks in patients 12 years and older. Already approved in the U.S., EU, UK, Japan, and other markets with strong commercial uptake ($49 million in 2025 U.S. sales), sebetralstat will bolster Chiesi Global Rare Diseases’ immunology franchise and support the group’s 2030 revenue target of €6 billion. The deal is expected to close in Q3 2026, subject to customary closing conditions including a successful tender offer. (Link)
  3. Atrium Health and WakeMed propose $2 billion strategic combination to expand services and create 3,300 jobs in North Carolina Atrium Health (part of Advocate Health) and Raleigh-based WakeMed have announced a proposed merger that includes a $2 billion investment in Wake County, aimed at expanding access across North Carolina and creating approximately 3,300 new healthcare jobs over five years. The combination would unite North Carolina’s largest health system with the Triangle’s leading community-based provider, enhancing specialty services (cancer, neurosciences, pediatrics), building the state’s largest nonprofit mental health network (>360 inpatient beds), and establishing its largest virtual care platform. Key initiatives include redevelopment of WakeMed’s Raleigh campus, hospital expansions, new Healthplex facilities, and strengthened medical education partnerships with Wake Forest University School of Medicine. The non-binding proposal requires approval from the Wake County Board of Commissioners and is subject to regulatory review. (Link)
  4. CareDx (NASD: CDNA) to acquire Naveris for $160 million upfront plus up to $100 million in milestones to enter viral-mediated cancer MRD surveillance CareDx, Inc. has entered into a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company specializing in blood-based molecular residual disease (MRD) monitoring for HPV-driven cancers. The transaction includes $160 million in upfront cash consideration and up to an additional $100 million contingent on revenue milestones. Naveris’ flagship NavDx® test, based on proprietary Tumor Tissue Modified Viral (TTMV®) DNA technology, is Medicare-reimbursed and addresses a $4.5 billion total addressable market in head and neck, anal, and other viral-mediated cancers. The company generated approximately $34 million in unaudited 2025 revenue (with Q1 2026 revenue of ~$12 million at 65% gross margin) and has performed over 130,000 commercial tests to date. The acquisition extends CareDx’s precision medicine strategy from transplant diagnostics into specialty oncology while remaining neutral to 2026 Adjusted EBITDA guidance. The deal is expected to close in Q3 2026. (Link)
  5. CareMetx expands its patient access platform through the strategic acquisition of U.S.-based patient services and TheraCom free goods pharmacy operations from Cencora, Inc. (NYSE: COR) CareMetx has successfully completed the acquisition of Cencora’s (COR) U.S. Hub consulting services and its TheraCom pharmacy business to create a more robust technology-enabled services platform. This transaction integrates Cencora’s extensive staffing and pharmacy infrastructure with CareMetx’s AI-driven workflow automation. The deal positions CareMetx to serve over 155 pharmaceutical brands, focusing on reducing treatment barriers and improving patient access to specialty medications. Cencora will transition into a preferred partner role, ensuring a seamless transition for existing clients while leveraging CareMetx’s specialized digital solutions to enhance patient journeys across the healthcare ecosystem. (Link)
  6. Odyssey Therapeutics targets up to $810 million valuation in Nasdaq IPO for autoimmune and inflammatory disease pipeline Odyssey Therapeutics has filed to raise up to $238.3 million in its U.S. initial public offering by offering 13.2 million shares priced between $16 and $18 each, targeting a valuation of up to $809.9 million. The Boston-based biopharmaceutical company is developing precision therapies for autoimmune and inflammatory diseases, with lead candidate OD-001 in a mid-stage (Phase 2) trial for ulcerative colitis. Odyssey plans to list on Nasdaq under the ticker “ODTX,” with J.P. Morgan, TD Cowen, and Cantor serving as lead underwriters. The IPO comes amid a strong resurgence in biotech listings and would provide capital to advance its clinical pipeline in high-unmet-need immune-mediated indications. (Link)
  7. Infinite Epigenetics acquires Tally Health a longevity company co-founded by Dr. David Sinclair, seeded by L Catterton, to build a vertically integrated epigenetic testing platform Infinite Epigenetics has completed the acquisition of Tally Health, marking a major consolidation in the longevity and biological age testing market. The deal combines Tally Health’s consumer-facing brand and TallyAge™ test with Infinite Epigenetics’ scientific infrastructure and DNA methylation datasets. Tally Health will operate as a standalone consumer brand within the Infinite Epigenetics ecosystem, gaining access to advanced diagnostic tools from the TruDiagnostic arm. The acquisition is intended to accelerate the development of personalized interventions for aging and shift the healthcare focus toward proactive longevity. L Catterton, an initial investor in Tally, sees the exit as a milestone in the commercialization of biological age metrics. (Link)
  8. Global clinical research organization Parexel acquires Vitrana to integrate its AI-powered pharmacovigilance platform into Parexel’s comprehensive patient safety and clinical development services Parexel has bolstered its patient safety capabilities through the acquisition of Vitrana, a provider of AI-driven pharmacovigilance technology. The deal allows Parexel to offer an end-to-end safety model that automates data processing for regulatory submissions, reducing the administrative burden on clinical trials. Vitrana’s system-agnostic platform will be integrated into Parexel’s global infrastructure, enabling pharmaceutical clients to achieve greater accuracy in adverse event reporting. This strategic move aims to improve operational efficiency and global compliance while maintaining a focus on high-quality clinical outcomes. Vitrana will operate as a Parexel company, keeping its leadership team to drive continued technological innovation. (Link)
  9. Enterprise oncology platform Azra AI acquires Thynk Health to expand its AI-driven incidental findings and lung cancer screening platform across 500 hospitals Azra AI has acquired Thynk Health to create a unified platform for managing incidental medical findings and cancer screenings. The merger brings together two leaders in the oncology workflow space, serving a combined customer base that includes five of the top ten U.S. health systems. By integrating Thynk Health’s specific expertise in lung cancer screening, Azra AI enhances its ability to identify and track patients from the moment a potential issue is spotted in imaging. The combined entity aims to eliminate patient handoff failures and accelerate the diagnosis of life-threatening conditions. Thynk Health’s leadership will join Azra AI to oversee the expansion of the incidental findings platform. (Link)
  10. Quality data management leader Medisolv, Inc. acquires Health Elements AI to enhance its automated data abstraction and clinical registry reporting capabilities for healthcare organizations Medisolv has acquired Health Elements AI to modernize its clinical data extraction processes using advanced artificial intelligence. The acquisition targets the labor-intensive process of manual chart reviews, aiming to support the 4,000 abstracters using Medisolv’s platform across 1,800 hospitals. By integrating Health Elements’ AI-first software, Medisolv enhances its ability to capture structured data for critical reporting to organizations like the American Heart Association. This move follows Medisolv’s recent acquisition of Lilac Software, reinforcing its commitment to reinventing quality data usage. The combined technology will help healthcare providers transition more effectively to value-based care models by improving data accuracy and reducing staff burden. (Link)
  11. Pinnaql acquires Pharma Resource Group to expand scientific, formulation, and manufacturing advisory capabilities Pinnaql, Inc., a 3 Boomerang Capital portfolio company, has acquired Pharma Resource Group, Inc. (PRG), a provider of analytical sciences, formulation development, scientific writing, manufacturing, and change control advisory services to the pharmaceutical and life sciences industries. This marks Pinnaql’s third tuck-in acquisition in the past 10 months and significantly strengthens its end-to-end offering across the product lifecycle — from laboratory innovation and scale-up to validation, quality systems, regulatory compliance, and commercial readiness. Founded in 2007, PRG brings deep formulation and manufacturing expertise that complements Pinnaql’s existing strengths in engineering, validation, and quality consulting. The deal advances Pinnaql’s strategy to build a scaled, multi-disciplinary advisory platform serving biopharma, medical device, and CDMO clients. (Link)
  12. UConn Health signs letters of intent to acquire Bristol Hospital and Day Kimball Hospital as part of statewide expansion UConn Health has signed letters of intent to acquire Bristol Health (anchored by 154-bed Bristol Hospital) and Day Kimball Hospital (104-bed facility in Putnam), advancing its strategy to build a broader community hospital network across Connecticut. The non-binding agreements aim to close the Bristol transaction by January 2027 and the Day Kimball deal by fall 2026, subject to regulatory approval via the state’s Certificate of Need process. Both independent community hospitals have faced financial challenges, with negative operating margins in recent years, and the affiliations are expected to provide financial stability, expand access to academic medical center expertise, and strengthen UConn Health’s competitive position. The moves follow UConn’s recent acquisition of Waterbury Hospital and align with state-supported efforts to preserve essential healthcare services in the region. (Link)
  13. Nationwide Medical acquires Dynamic Healthcare Services (DHS) to expand home respiratory and durable medical equipment footprint Nationwide Medical, a leading provider of specialized respiratory care and home healthcare solutions, has acquired Dynamic Healthcare Services (DHS), a well-established provider of home respiratory supplies, durable medical equipment (DME), and oxygen therapy products serving Pennsylvania, New Jersey, and surrounding markets. The strategic acquisition strengthens Nationwide Medical’s regional presence and enhances its clinical programming for OSA, COPD, and other chronic respiratory conditions through DHS’s patient-centric model and strong local clinician relationships. This transaction expands access to comprehensive home-based care, including sleep therapy support, patient monitoring programs, and advanced equipment, while integrating DHS’s expertise with Nationwide Medical’s national infrastructure and remote monitoring capabilities. The deal aligns with Nationwide Medical’s growth strategy focused on improving therapy compliance and patient outcomes in the home medical equipment sector. (Link)
  14. The Ensign Group (NASD: ENSG)  acquires real estate and expands operations in Texas with new post-acute care campus The Ensign Group, Inc. has acquired the real estate and operations of a newly constructed 124-bed skilled nursing and rehabilitation facility in Texas, marking its continued expansion in the state. This transaction adds a modern, purpose-built campus to Ensign’s portfolio and brings the total number of operating facilities in Texas to 52. The acquisition aligns with Ensign’s disciplined “pay-for-performance” model and its strategy of entering high-quality, well-located assets in attractive markets. Financial terms were not disclosed. This move further strengthens Ensign’s presence in one of its key growth states and supports its long-term goal of portfolio diversification and operational scale in the post-acute care sector. (Link)
  15. Baystate Health and Trinity Health Of New England sign definitive agreement for integration of Mercy Medical Center Baystate Health has entered into a definitive agreement with Trinity Health Of New England to transition ownership of Mercy Medical Center (a 182-bed acute care hospital in Springfield, MA), its joint venture affiliates, and medical group entities to Baystate Health, subject to regulatory approvals. The transaction will allow Baystate to preserve Mercy’s nonprofit mission and Catholic legacy while providing financial stability and operational support to ensure long-term sustainability of high-quality local care in Western Massachusetts. Trinity Health Of New England will retain ownership of its Brightside for Families and Children services as well as continuing care operations, including Mercy LIFE, Beaven Kelly Home, and Saint Luke’s Home. The move addresses Mercy’s ongoing financial pressures from reimbursement challenges, outpatient shifts, and staffing shortages, strengthening regional access and positioning Baystate as a stronger safety-net provider for the Pioneer Valley. (Link)
  16. AI automation firm 1520ai acquires data insights firm Hospice Analytics to combine hospice-native artificial intelligence with established market utilization datasets. 1520ai has finalized the acquisition of Hospice Analytics, a firm with 20 years of experience in hospice data analysis. The merger unites 1520ai’s predictive modeling with Hospice Analytics’ deep market trends and utilization data to create a new platform focused on regulatory compliance and clinical quality. 1520ai, which has minority backing from simPAL Solutions, plans to use the acquisition to provide hospice providers with real-time answers to operational and financial questions. Hospice Analytics will maintain its branding and its partnership with the National Hospice Locator. (Link)
  17. Superior Health Holdings a Renovus Capital Partners portfolio company, acquires Chant Healthcare to expand its home health and hospice services into the Oklahoma market Superior Health Holdings has expanded into Oklahoma through the acquisition of Chant Healthcare, which operates as Compassion Homecare and Sans Bois Hospice. Backed by Renovus Capital Partners, Superior intends to leverage Chant’s strong presence in 11 Oklahoma counties and its large dual-eligible Medicaid patient base. The acquisition provides a strategic foothold for further expansion into the Oklahoma City and Tulsa markets. Chant Healthcare’s leadership will remain in place to manage local operations while utilizing Superior’s broader administrative and clinical infrastructure. This transaction marks Superior’s entry into its second state, following its established presence in Arkansas, and focuses on scaling rural healthcare delivery through specialized hospice services. (Link)
  18. The Medical University of South Carolina and Revival Healthcare Capital establish a five-year strategic innovation partnership to fund and scale next-generation medical technology solutions The Medical University of South Carolina (MUSC) has entered into a five-year partnership with private equity firm Revival Healthcare Capital to accelerate the commercialization of medical device innovations. Under the agreement, MUSC will provide clinical expertise and validation support for Revival’s portfolio companies, while Revival will provide the capital and operational leadership necessary to scale MUSC-originated technologies. This collaboration is designed to bridge the gap between academic research and commercial medical solutions. The partnership focuses on identifying unmet clinical needs and deploying high-impact medical devices into the healthcare market. Both organizations aim to create a repeatable model for innovation that improves patient outcomes through targeted investment and clinical rigor. (Link)

Venture Deals and Other

  1. DTC health platform Musely secures $360 million in non-dilutive capital from General Catalyst to accelerate customer acquisition for its dermatology and menopause care lines Musely has secured a $360 million capital commitment from General Catalyst through a non-dilutive financing structure. This arrangement allows Musely to fund aggressive marketing and customer acquisition efforts without giving up equity in the company. The funding will primarily support Musely’s core prescription skincare business and its recent expansion into the menopause care market. By utilizing non-dilutive capital, Musely maintains control over its operations while leveraging General Catalyst’s resources to scale its digital platform. The deal highlights a growing trend of high-growth, profitable direct-to-consumer health companies choosing creative financing over traditional venture rounds to fuel expansion. Musely plans to use the funds to reach millions of new patients globally. (Link)
  2. Bio-inspired BCI startup Axoft secures $55 million in Series A funding led by C.P. Group Innovation, with participation from Hillhouse Investment and Gaorong Ventures Axoft has raised $55 million in an oversubscribed Series A round to advance its implantable brain-computer interface (BCI) technology. The round, led by C.P. Group Innovation, included participation from Hillhouse, Gaorong, and the Stanford President’s Venture Fund, bringing Axoft’s total funding to over $60 million. Axoft is developing bio-inspired, soft implants that aim to provide long-term stability for neural communication without damaging brain tissue. The funding will support the expansion of global clinical trials, including the company’s first-in-human studies. This investment underscores the high demand for scalable BCI solutions that can treat neurological disorders. Axoft intends to use the capital to navigate regulatory approvals and scale its manufacturing capabilities. (Link)
  3. Truentity Health secures $35 million in oversubscribed Series A funding led by Evidenced VC, with participation from K-Street Capital, Cofounders Capital, and Tweener Fund. Truentity Health has closed a $35 million Series A round to scale its pharmacy-led clinical care model, which enables community pharmacies to provide chronic disease management services. The investment was led by Evidenced VC and saw participation from regional investors like Cofounders Capital and Tweener Fund. Truentity provides an AI platform that supports pharmacies in delivering reimbursable services such as remote patient monitoring and medication therapy management. The capital will be used to expand the company’s network into new state markets throughout 2026. By turning local pharmacies into clinical hubs, Truentity aims to improve healthcare access in rural areas and provide pharmacies with new, sustainable revenue streams. (Link)
  4. Prescription infrastructure startup Photon secures $16 million in Series A funding led by Healthier Capital, with participation from Notation, Flare Capital, and Evidenced Photon has closed a $16 million Series A funding round to modernize the digital prescription experience for patients and providers. The round was led by Healthier Capital and included participation from Flare Capital and Notation, bringing Photon’s total capital raised to over $25 million. Photon provides an API-driven infrastructure that allows patients to see real-time prescription pricing and stock availability at retail pharmacies. The new funds will support the expansion of Photon’s engineering team and the growth of its commercial partnerships with health systems and digital health brands. By simplifying the prescription routing process, Photon aims to reduce the estimated 20-30% of prescriptions that are currently abandoned by patients. (Link)
  5. AI pathology developer Techcyte bags $15 million in funding led by Van Tuyl Companies, with participation from strategic investors Zoetis Inc. (NYSE: ZTS) and Mayo Clinic. Techcyte has raised $15 million to scale its AI-powered digital pathology platform and drive the company toward profitability. The financing round was led by Van Tuyl Companies and saw continued support from Zoetis (ZTS) and Mayo Clinic. As part of the partnership, Techcyte will leverage Mayo Clinic’s massive dataset of 17 million pathology slides to further train its diagnostic algorithms. The Techcyte Fusion platform is designed to unify human, veterinary, and environmental pathology workflows into a single digital interface. The investment will be used to expand Techcyte’s global footprint and address the critical shortage of laboratory professionals by automating routine and complex diagnostic tasks. (Link)
  6. UnityAI launches its StaffOps platform for outpatient care following an $8.5 million Series A funding round led by Third Prime, with participation from Nashville Capital Network. UnityAI has introduced its AI-powered staffing and operations platform, StaffOps, following an $8.5 million Series A round led by Third Prime. The funding, which included participation from Whistler Capital Partners and Max Ventures, supports the company’s mission to optimize the outpatient healthcare workforce. StaffOps uses agentic AI to handle patient interactions and coordinate clinical tasks, currently managing over 300,000 interactions monthly. UnityAI has already partnered with large groups like Tennessee Oncology to improve clinical throughput and patient access. The new capital will be used to expand UnityAI’s go-to-market team and enhance its EHR integration capabilities, ensuring AI-driven tasks are safe, traceable, and highly efficient for medical staff. (Link)
  7. Specialty clinic automation startup TriFetch raises $1.9 million in pre-seed funding led by Nexus Venture Partners with participation from high-profile angel investors TriFetch has emerged from stealth with $1.9 million in pre-seed capital to develop AI automation tools specifically for independent medical practices. Nexus Venture Partners led the round, which also featured investment from notable angels affiliated with Google and Hippocratic AI. TriFetch’s platform acts as an automation layer that manages administrative tasks like patient scheduling, referral processing, and prior authorizations. Unlike traditional EHRs, TriFetch integrates with existing workflows to reduce the daily “paperwork” burden on clinicians. The funding will be used to build out the core product and expand its reach to more specialty clinics across the U.S., focusing on improving clinic profitability and reducing staff burnout. (Link)
  8. Depth Health raises $1 million in seed funding led by Green Harvest Capital Industries (GHC Industries) to scale its AI-driven hospital throughput optimization platform Depth Health has secured $1 million in seed financing to advance its Augmented Surveillance Intelligence (ASI) platform, which optimizes hospital patient flow and bed management. The funding round was led by Green Harvest Capital Industries, whose CEO, Ankit Patel, will join Depth Health’s Board of Directors. The capital will be used to enhance Depth Health’s explainable AI models, which provide real-time recommendations for patient placement and discharge. By joining the GHC Industries portfolio, Depth Health gains access to a broader ecosystem of clinical intelligence technologies. The investment aims to help hospitals reduce throughput bottlenecks and improve financial performance through data-backed operational efficiency. (Link)
  9. Virchu Sciences secures first institutional funding round to advance AI-powered oncology drug discovery platform Virchu Sciences has closed its first institutional investment round led by the Ohio Innovation Fund, with participation from JobsOhio Ventures and Rev1 Ventures. The Columbus, Ohio-based company operates at the intersection of AI, pharma, biotech, and academic research, developing multimodal AI solutions to accelerate drug discovery, advance treatment identification, and enable precision oncology testing. The new capital will support expansion of its data engineering and AI team, enhancement of its Data Discovery and Delivery Platform, and go-to-market efforts targeting academic institutions and commercial partners. The round underscores strong Ohio ecosystem support for AI-enabled life sciences innovation. (Link) (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 2nd, 2026

LECO_Weekly-Healthcare-News_2-2-2026Download
  1. Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
  2. Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
  3. Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
  4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
  5. Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
  6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
  7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
  8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
  9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
  10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
  11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
  12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
  13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
  14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
  15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)

Venture and Other News  

  1. Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
  2. Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
  3. Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
  4. Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
  5. Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
  6. TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
  7. Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)